Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
05/2007
05/30/2007EP1790351A1 Permucosal composition and method of improving permucosal absorption
05/30/2007EP1790346A2 Use of bile acid or bile salt fatty acid conjugates
05/30/2007EP1790335A1 Composition and its use for the manufacture of a medicament for treating, prophylactically treating, preventing cancer and/or infections in the urinary tract
05/30/2007EP1790334A2 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
05/30/2007EP1790235A1 Method for producing capsinoid-containing microcapsule
05/30/2007EP1789391A1 Bivalent linkers and conjugates thereof
05/30/2007EP1789361A1 Water-soluble nanoparticles stabilized with multi-functional group ligands and method of preapation thereof
05/30/2007EP1789093A2 Antibody vaccine conjugates and uses therefor
05/30/2007EP1789092A2 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
05/30/2007EP1789091A2 Prodrugs containing novel bio-cleavable linkers
05/30/2007EP1789060A1 Compositions comprising compounds capable of forming a reversible bond or association with gaseous nitric oxide
05/30/2007EP1789059A2 Glycosylceramide adjuvant for saccharide antigens
05/30/2007EP1789057A2 Neuroprotective effect of solubilized udca in focal ischemic model
05/30/2007EP1789019A2 Powders containing novel oligosaccharide mixtures and methods for producing the same
05/30/2007EP1531797A4 Biodegradable block copolymeric compositions for drug delivery
05/30/2007EP1496925A4 Use of interleukin-24 to treat ovarian cancer
05/30/2007EP1492560A4 Use of interleukin-19 to treat cervical cancer
05/30/2007EP1450767B1 Microspherules containing a pleuromutilin derivative
05/30/2007EP1406568B1 Sequential drug delivery systems
05/30/2007EP1313446A4 Water soluble microflake through air-gap and process therefore
05/30/2007EP1299108A4 A parasiticidal formulation and a method of making this formulation
05/30/2007EP1285655B1 Stabilized pharmaceutical compositions containing the calcium channel blocker azelnidipine
05/30/2007EP1107791B1 Hydrogel compositions for the controlled release administration of growth factors
05/30/2007EP1074255B1 Pharmaceutical gel formulation comprising a tricyclic compound (fk-506/tacrolimus)
05/30/2007EP1019010B1 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
05/30/2007EP0885393B1 Graphitic nanotubes in luminescence assays
05/30/2007CN1972717A Binary thermo-gelling composition
05/30/2007CN1972693A Invert emulsion composition containing calcitriol and clobetasol 17-propionate, and uses thereof in cosmetics and dermatology
05/30/2007CN1972691A Intranasal benzodiazepine compositions
05/30/2007CN1972676A Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
05/30/2007CN1972671A Microspheres comprising protein and showing injectability at high concentrations of said agent
05/30/2007CN1972668A Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel
05/30/2007CN1972665A Injectable depot compositions and uses thereof
05/30/2007CN1970591A Biodegradable crosslinked polyethylenimine and its uses
05/30/2007CN1970579A High substitution degree carboxymethyl indianbread polysaccharide and its preparation method and uses
05/30/2007CN1970572A Interferon alpha mutant and its polyethylene glycol derivative
05/30/2007CN1970571A G-csf analog compositions and methods
05/30/2007CN1970086A Monomodified PEGylated insulin and its preparation method
05/30/2007CN1970085A Orally disintegrating tablet of ubenimex and preparation method thereof
05/30/2007CN1970084A Hydrotalcite-like vesicle compounds and method for preparing same
05/30/2007CN1970079A Vagina effervescence tablet of recombinant human interferon alpha-2a and preparation process thereof
05/30/2007CN1970056A Taste improved 'Xin Xue' powder
05/30/2007CN1970024A Pharmaceutical composition for treating acne and application method thereof
05/30/2007CN1969992A Pharmaceutical composition for treating acne and application method thereof
05/30/2007CN1969971A Transdermal absorption formulation of total alkaloid of common monkshood root and preparation process thereof
05/30/2007CN1969964A Compound oral Chinese medicinal formulation for treating gallbladder diseases
05/30/2007CN1969960A Pharmaceutical composition for treating acne and application method thereof
05/30/2007CN1969929A Dry coating sustained-release tablet for treating arthritis and preparation process thereof
05/30/2007CN1969889A Enteric-coated multilayer encapsulated probiotic microcapsule and preparation method thereof
05/30/2007CN1969874A Externally applied pharmaceutical composition of abafungin
05/30/2007CN1969861A Sustained release system of clozapine solid liposome microparticle
05/30/2007CN1969854A Sustained release formulation of raltitrexed and preparation method thereof
05/30/2007CN1969850A Taste masked suspension prescription for treating infant cold and method for preparing same
05/30/2007CN1969849A Stable pharmaceutical composition containing pitavastatin calcium and preparation process thereof
05/30/2007CN1969847A Pharmaceutical composition
05/30/2007CN1969830A Itraconazole liposome and preparation process thereof
05/30/2007CN1969829A Clozapine encapsulated solid lipid microparticle and preparation process thereof
05/30/2007CN1969828A Anticancer sustained release injection containing mesenchyme hydrolytic agent
05/30/2007CN1969827A Anti-solid tumor composition containing epothilone and mesenchyme hydrolytic agent
05/30/2007CN1969826A Fluorouracil and its synergist carried sustained release agent
05/30/2007CN1969825A Sustained release agent containing fluorouracil and synergist thereof
05/30/2007CN1969824A Anticancer sustained release agent containing fluorouracil and synergist thereof
05/30/2007CN1969823A Sustained release agent containing fluorouracil and synergist thereof
05/30/2007CN1969820A Anticancer pharmaceutical composition
05/30/2007CN1969819A Anticancer pharmaceutical composition
05/30/2007CN1969818A Anticancer sustained release injection containing epothilone derivatives
05/30/2007CN1969817A Anticancer composition
05/30/2007CN1969816A Anticancer sustained release agent containing epothilone
05/30/2007CN1969815A Sustained release agent of curcumin and preparation method thereof
05/30/2007CN1969814A Nasal administered preparation of melatonin
05/30/2007CN1318481C Biodegradable fluorescent polyphosphonitrile and process for synthesis thereof
05/30/2007CN1318453C Fluorescence labeling hydrophobic modified chitin polymer, its preparation method and application
05/30/2007CN1318450C Modified/chimeric super-antigens and their use
05/30/2007CN1318446C Transferrin receptor protein of Moraxella
05/30/2007CN1318434C Mitochondrially targeted antioxidants
05/30/2007CN1318093C Injections for eye tissue containing drug bound to polyethylene glycol
05/30/2007CN1318092C Immunity treatment composition containing antibody-cytokine fusion protein mediated and angiogenesis inhibitor
05/30/2007CN1318090C Medicine composition for improving stability of human urine kininogenase
05/30/2007CN1318089C Use of botulinum toxin for treatment of articular pathologies
05/30/2007CN1318087C Removing albumin nerve growth factor agent
05/30/2007CN1318084C Neuroprotective peptides
05/30/2007CN1318030C Methods and compositions useful in enhancing oxygen delivery to cells
05/30/2007CN1318026C Solid pharmaceutical formulations comprising modafinil
05/30/2007CN1318024C Beta-cyclodextrin/phenylpropanol inclusion and its preparing method
05/30/2007CN1318023C Chemically-defined non-polymeric valency platform molecules and conjugates thereof
05/30/2007CN1318021C Rapidly disintegrating table and process for manufacture thereof
05/30/2007CN1318019C Solid dispersion comprising two different polymer matrixes
05/29/2007US7223837 Anticancer prodrugs, enhance enzymatic activation rates
05/29/2007US7223803 Polyethylene (glycol) derivatives with proximal reactive groups
05/29/2007US7223797 New salts such as meldonium dihydrogen phosphate, meldonium hydrogen fumarate or meldonium orotate; nonhygroscopic and/or increased thermal stability and/or lasting action
05/29/2007US7223790 Dimeric compounds and their use as anti-viral agents
05/29/2007US7223770 Tocopherol-modified therapeutic drug compounds
05/29/2007US7223748 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
05/29/2007US7223741 nucleic acids containing unmethylated cytosine-guanine (CpG) dinucleotides activate lymphocytes in a subject and redirect a subject's immune response from a Th2 to a Th1
05/29/2007US7223739 Adjuvanted genetic vaccines
05/29/2007US7223735 Abuse resistant lysine amphetamine compounds
05/29/2007US7223600 cell is contacted with a photosentistising agent, cell is irradiated with light to activate photosentisitising agent, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination
05/29/2007US7223571 Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
05/29/2007US7223570 Such as cyclo-glucopyranosyl derivatives via glucanotransferases, galactosidases, hydrolases, and glycosidases; for use in foods, cosmetics
05/29/2007US7223561 Culturing yeast transformed with albumin-encoding nucleotide sequence in a fermentation medium; gene expression, separation, conditioning, adding sodium octanoate; cationic exchange chromatography, elution, ultrafiltration, sterilization, diafiltration, filling vessel
1 ... 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 ... 1712